Ann: Pronounced survival benefit in LuPIN interim trial data, page-9

Maybe because 177Lu-PSMA-617 is fantastic treatment getting fantastic results.


Clinical outcome of standardized 177Lu-PSMA-617 therapy in metastatic prostate cancer patients receiving 7400 MBq every 4 weeks.
Rasul S, et al. Eur J Nucl Med Mol Imaging. 2020

The majority of patients were previously treated with abiraterone/enzalutamide (69%) and docetaxel/cabazitaxel (67%). In total, 79% of the patients showed a decrease in PSA (median PSA decrease from 66 to 19.8, range 0.7-4563 μg/L, P < 0.001) 1 month after the 3rd therapy cycle. Among them, 58% and 35% demonstrated a PSA-decline of > 50% and > 80%, respectively. Median OS was 119 weeks; median PFS was 25 weeks.

https://www.ncbi.nlm.nih.gov/m/pubmed/31781834/